Cancer patients can respond very differently to the same treatment, while current testing may not reliably identify the therapy most likely to work for each tumor.
R&D Focus
InheRET empowering individuals to accurately identify their risk for hereditary conditions
Innovative Solution
InheRET platform provides a personalized medicine approach to curb barriers that patients and clinicians may face for the prevention of and early detection of hereditary disease. The platform identifies patients at increased risk for hereditary cancers and offers next-step recommendations and tailored educational resources for users.
Investment Funding
Last Funding Stage
Seed
Total Funding Amount
3.18M
Last Funding Amount
580.K
Last Funding Date
02-05-2022
Startup Stage
Seed
Lead Investors
National Cancer Institute, Accelerate Blue Fund
Revenue
$1M to $10M
People
Founders
Amanda Cook
David F. Keren
Kara Milliron
Lee Schroeder
Lynn McCain
About
InheRET platform provides a personalized medicine approach to curb barriers that patients and clinicians may face for the prevention of and early detection of hereditary disease. The platform identifies patients at increased risk for hereditary cancers and offers next-step recommendations and tailored educational resources for users.
Something missing or incorrect on this page? Help us enrich this information
